Distribution of Mutations in the Tumor-Derived VH Sequences
| Patient . | Ig Clone . | GL Donor . | R:Sobs (CDR)* R:Sobs (FWR) . | Rexp (CDR) . | P(CDR)† P (FWR) . |
|---|---|---|---|---|---|
| PAI | IgG/IgM1 | V3-23 | 2.8 (14:5) | 6.0 | <.001 |
| 1.0 (7:7) | <.001 | ||||
| IgM2 | V4-59 | 4.5 (9:2) | 6.0 | .100 | |
| (aberrant) | 10.0 (20:2) | .120 | |||
| BLO | IgG/IgM | V3-7 | 5.0 (10:2) | 4.0 | <.001 |
| 1.0 (4:4) | <.001 | ||||
| BAR | IgG/IgM | V1-46 | ∞ (4:0) | 2.0 | .001 |
| 3.0 (6:2) | .026 | ||||
| SAM | IgG | V3-74 | 4.3 (13:3) | 5.0 | <.001 |
| 1.6 (8:5) | <.001 | ||||
| IgM | V3-74 | 2.8 (11:4) | 5.0 | .002 | |
| 1.0 (6:6) | <.001 | ||||
| LAR | IgG | DP-58 | 12.0 (12:1) | 5.0 | <.001 |
| 1.6 (8:5) | <.001 | ||||
| IgM | DP-58 | 16.0 (16:1) | 5.0 | <.001 | |
| 0.6 (4:7) | <.001 |
| Patient . | Ig Clone . | GL Donor . | R:Sobs (CDR)* R:Sobs (FWR) . | Rexp (CDR) . | P(CDR)† P (FWR) . |
|---|---|---|---|---|---|
| PAI | IgG/IgM1 | V3-23 | 2.8 (14:5) | 6.0 | <.001 |
| 1.0 (7:7) | <.001 | ||||
| IgM2 | V4-59 | 4.5 (9:2) | 6.0 | .100 | |
| (aberrant) | 10.0 (20:2) | .120 | |||
| BLO | IgG/IgM | V3-7 | 5.0 (10:2) | 4.0 | <.001 |
| 1.0 (4:4) | <.001 | ||||
| BAR | IgG/IgM | V1-46 | ∞ (4:0) | 2.0 | .001 |
| 3.0 (6:2) | .026 | ||||
| SAM | IgG | V3-74 | 4.3 (13:3) | 5.0 | <.001 |
| 1.6 (8:5) | <.001 | ||||
| IgM | V3-74 | 2.8 (11:4) | 5.0 | .002 | |
| 1.0 (6:6) | <.001 | ||||
| LAR | IgG | DP-58 | 12.0 (12:1) | 5.0 | <.001 |
| 1.6 (8:5) | <.001 | ||||
| IgM | DP-58 | 16.0 (16:1) | 5.0 | <.001 | |
| 0.6 (4:7) | <.001 |
Abbreviations: GL, germline; CDR, complementary-determining region; FWR, framework region.
R:S is the ratio of replacement (R) to silent (S) mutations observed in CDRs or FWRs, as compared with those expected by chance alone.
Probability of obtaining the number of R mutations by chance alone.P < .05 is considered significant for either excess of R mutations (CDR) or lack of R mutations (FWR).